uniQure: Positive 3-Year AMT-130 Data Leads To Pre-BLA FDA Meeting And Beyond

Qure achieved a 75% statistically significant slowing of Huntington's Disease progression with AMT-130 in a pivotal phase 1/2 ...

uniQure Stock Doubles On Promising Data From Huntington's Disease Trial

Qure N.V. (NASDAQ:QURE) on Wednesday released topline data from the pivotal Phase 1/2 study of AMT-130 for Huntington’s ...